Immunotherapy Drugs market Size To Expand at a Notable CAGR Of 8.70 % During 2022 - 2030

Pune, India, April 2022 /MRFR Press Release/- Market Research Future published a half-cooked research report on the global immunotherapy drugs market.

Market Highlights

The immunotherapy drugs market will be achieving a CAGR of 8.70% between 2022 and 2030, reveals Market Research Future (MRFR). 

Therapies like chemotherapy and other radiotherapy is not effective in melanoma cancer. Immunotherapy show a better result for the treatment of melanoma cancer. Immunotherapies are used for limited number of cancer treatment mostly haematological, but they show better results where other therapy is not effective. Increasing cancer population, increasing healthcare expenditure with rising government support for research & development are the major driving factor for the market. Majority of manufacturers are actively working in research & development of immunotherapy drugs because of huge necessities like better treatment. Some manufactures are trying to introduce different immunotherapeutic product in the market which will be more effective than present treatment. Many other factors are responsible for increasing the market of immunotherapy drugs like unavailability of absolute treatment and continuous increasing cancer population. On the other hand, long time approval and different adverse effect may restrain the growth of the market

Segmentation

The global Immunotherapy Drugs market is segmented based on therapy area, type of drugs, end user and region.

On the basis therapy area, the market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases and others. Further, on the basis of type of drugs the market is segmented into Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins and Others. Further end user is segmented into hospitals & clinics, ambulatory surgical centers, others.

Explore In-depth Details: Immunotherapy Drugs Market Research Report

Regional Analysis

Asia Pacific immunotherapy drugs market is segmented into Japan, China, India, Australia, Republic of Korea and Rest of Asia Pacific. The major driving factor for the market is increasing number of patient population in India and China. China and India are the major contributor in the Asia Pacific immunotherapy drugs market. According to the NCIP, 0.33 million of the people in India are suffering from cancer and the number is continuously increasing owing to the changing lifestyle. Moreover, presence of huge patient population and increasing government support for research & development will fuel the growth of the market in India. China holds the second largest market for immunotherapy drugs market which is followed by Japan. Increasing government support, rapidly developing economy and increasing healthcare expenditure will boost the growth of China and Japan market. Moreover, availability of highly skilled healthcare professionals and rising acceptance of these therapies and increasing demand for the treatment have provided push for the growth of the market in these countries. Australia and Rest of Asia Pacific contribute the least share in the market.

Key players

Some of the key players in the global Immunotherapy Drugs market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.). Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Eli Lilly and Company (U.S.), Johnson & Johnson (U.S.), and AstraZeneca plc (U.K.)